What is HC Wainwright’s Forecast for Neurogene Q3 Earnings?

Neurogene Inc. (NASDAQ:NGNE – Free Report) – Equities researchers at HC Wainwright cut their Q3 2026 earnings estimates for shares of Neurogene in a research report issued on Wednesday, August 12th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($1.36) per share for the quarter, down from their prior estimate of ($1.34). HC Wainwright has a “Buy” rating and a $65.00 price target on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($5.63) per share. HC Wainwright also issued estimates for Neurogene’s Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($5.44) EPS, Q1 2027 earnings at ($1.22) EPS, Q2 2027 earnings at ($1.24) EPS, Q3 2027 earnings at ($1.26) EPS, Q4 2027 earnings at ($1.27) EPS and FY2027 earnings at ($4.99) EPS.

Get Neurogene alerts:

Neurogene (NASDAQ:NGNE – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.11).

A number of other research firms also recently weighed in on NGNE. Rodman & Renshaw initiated coverage on shares of Neurogene in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 price target on the stock. UBS Group set a $70.00 price target on Neurogene in a research note on Wednesday, June 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Friday, July 17th. Canaccord Genuity Group lowered their price objective on shares of Neurogene from $180.00 to $166.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Guggenheim lifted their price target on shares of Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Neurogene presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Get Our Latest Stock Report on NGNE

Neurogene Price Performance

NGNE stock opened at $35.63 on Friday. Neurogene has a 52-week low of $15.93 and a 52-week high of $43.66. The firm has a market capitalization of $712.96 million, a P/E ratio of -7.08 and a beta of 1.70. The company’s 50 day simple moving average is $33.92 and its 200-day simple moving average is $26.83.

Insider Buying and Selling at Neurogene

In other news, CFO Christine Mikail Cvijic sold 4,200 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $36.13, for a total value of $151,746.00. Following the completion of the sale, the chief financial officer owned 84,040 shares of the company’s stock, valued at approximately $3,036,365.20. The trade was a 4.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 9,600 shares of company stock worth $339,932 in the last 90 days. 11.68% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Neurogene

Several institutional investors have recently made changes to their positions in NGNE. BlackRock Inc. bought a new stake in shares of Neurogene during the second quarter worth about $33,274,000. Balyasny Asset Management L.P. purchased a new stake in Neurogene in the 3rd quarter valued at about $12,114,000. Logos Global Management LP bought a new position in shares of Neurogene during the 4th quarter worth approximately $4,017,000. Jennison Associates LLC boosted its stake in shares of Neurogene by 35.3% in the 4th quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock worth $10,982,000 after buying an additional 138,999 shares during the last quarter. Finally, Deutsche Bank AG purchased a new stake in shares of Neurogene during the second quarter valued at approximately $3,354,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

About Neurogene

(Get Free Report)

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.

Read More

• Five stocks we like better than Neurogene
• Inside Teledyne’s Bold Bet on the Future of Medical Imaging
• Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
• Asian Market Circuit Breakers Hit Stocks, Not AI Demand
• Riot Platforms Re-Wires the Ledger for a $9B AI Power Play

Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.